Cao Jun-Xia, You Jia, Wu Li-Hua, Luo Kai, Wang Zheng-Xu
Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China.
World J Clin Cases. 2022 Sep 26;10(27):9714-9726. doi: 10.12998/wjcc.v10.i27.9714.
Currently, ongoing trials of mesenchymal stem cells (MSC) therapies for coronavirus disease 2019 (COVID-19) have been reported.
In this study, we investigated whether MSCs have therapeutic efficacy in novel COVID-19 patients.
Search terms included stem cell, MSC, umbilical cord blood, novel coronavirus, severe acute respiratory syndrome coronavirus-2 and COVID-19, applied to PubMed, the Cochrane Controlled Trials Register, EMBASE and Web of Science.
A total of 13 eligible clinical trials met our inclusion criteria with a total of 548 patients. The analysis showed no significant decrease in C-reactive protein (CRP) levels after stem cell therapy ( 0.11). A reduction of D-dimer levels was also not observed in patients after stem cell administration ( 0.82). Furthermore, interleukin 6 (IL-6) demonstrated no decrease after stem cell therapy ( 0.45). Finally, we investigated the overall survival (OS) rate after stem cell therapy in COVID-19 patients. There was a significant improvement in OS after stem cell therapy; the OS of enrolled patients who received stem cell therapy was 90.3%, whereas that of the control group was 79.8% ( 0.02).
Overall, our analysis suggests that while MSC therapy for COVID-19 patients does not significantly decrease inflammatory markers such as CRP, D-dimer and IL-6, OS is improved.
目前，已有关于间充质干细胞（MSC）治疗2019冠状病毒病（COVID-19）的正在进行的试验报道。
在本研究中，我们调查了MSC对新型冠状病毒肺炎患者是否具有治疗效果。
检索词包括干细胞、MSC、脐带血、新型冠状病毒、严重急性呼吸综合征冠状病毒2和COVID-19，应用于PubMed、Cochrane对照试验注册库、EMBASE和科学网。
共有13项符合条件的临床试验满足我们的纳入标准，共计548例患者。分析显示，干细胞治疗后C反应蛋白（CRP）水平无显著下降（0.11）。干细胞给药后患者的D-二聚体水平也未观察到降低（0.82）。此外，干细胞治疗后白细胞介素6（IL-6）无下降（0.45）。最后，我们调查了COVID-19患者干细胞治疗后的总生存率（OS）。干细胞治疗后OS有显著改善；接受干细胞治疗的入组患者的OS为90.3%，而对照组为79.8%（0.02）。
总体而言，我们的分析表明，虽然MSC治疗COVID-19患者不会显著降低CRP、D-二聚体和IL-6等炎症标志物，但可改善OS。
Zotero 插件
